Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Contract Revenue Recognized

The following table provides the contract revenue recognized by revenue source for the years ended December 31, 2025 and 2024 (in thousands):

	December 31,
	2025		2024
Pharmaceutical Development Segment
License Agreement	$	—	$	49
Pharmaceutical development and other	2,153		3,567
Total contract revenue	$	2,153	$	3,616

Schedule of Contract with Customer Liability

The Company’s contract liabilities are presented as deferred income in the consolidated balance sheets (in thousands):

	December 31, 2025
Pharmaceutical Development Segment
Beginning balance	$	1,500
Additions to deferred income	1,800
Income recognized (1)	(3,300)
Ending balance	$	—
(1) Included as a component on the gain of sale of MOD3 assets